Adrenaline veterinary grade API intended for sterile injectable solutions is handled as an oxygen-sensitive catecholamine with a chiral centre; the pharmacologically active form is the L-isomer. Industrial liquid preparation requires pre-dissolution nitrogen blanketing because oxidation to adrenochrome accelerates above pH 4.0 and in the presence of trace transition-metal ions. The solution is compounded to a final concentration of 1.0 mg/mL (1:1000) or 0.1 mg/mL (1:10,000) using Water for Injection that has been purged with filtered nitrogen to a dissolved oxygen level not exceeding 0.5 mg/L. Sodium metabisulfite is added at 0.05–0.2% w/v; disodium edetate is included at 0.01–0.05% w/v in some licensed formulations to chelate iron and copper ions that catalyse catechol oxidation. The pH is adjusted with dilute hydrochloric acid to 3.0–3.8 before final volume adjustment, because the free base is poorly soluble above pH 5.0 and oxidation kinetics increase sharply under neutral conditions. Bulk solution is passed through a 0.45 µm polyethersulfone prefilter followed by a 0.22 µm sterilising-grade polyvinylidene fluoride membrane into depyrogenated Type I borosilicate glass vials or ampoules. Terminal steam sterilisation at 121 °C is generally avoided because sulfite-protected adrenaline shows measurable pH drift and adrenaline loss above 100 °C; aseptic filtration followed by laminar-flow filling is the standard terminal sterile operation. Published data on terminal steam sterilisation of veterinary adrenaline injection is limited, and the aseptic route is retained unless a heat-stability study demonstrates otherwise. The filled units are closed under nitrogen overlay with chlorobutyl rubber stoppers and aluminium caps. Release testing includes assay by liquid chromatography against pharmacopoeial reference standards according to Ph. Eur. 2.2.29 and USP <621>, sterility according to Ph. Eur. 2.6.1 or USP <71>, bacterial endotoxins according to Ph. Eur. 2.6.14 or USP <85>, and sub-visible particulate matter according to Ph. Eur. 2.9.19 or USP <788>. The finished products are used in companion animal emergency medicine for anaphylaxis and cardiopulmonary resuscitation at labelled concentrations of 1.0 mg/mL and in large animal intravenous support at 0.1 mg/mL.

On industrial filling lines, the dominant batch-to-batch failure mode is not sterility but oxidation-induced colour development during hold time. Stainless steel 316L product-contact surfaces must be mechanically polished to a surface roughness not exceeding 0.8 µm Ra and passivated, because rough surfaces retain iron oxide residues that catalyse adrenochrome formation. Nitrogen sparge lines are fitted with 0.2 µm hydrophobic filters, and the overlay pressure is maintained at 0.2–0.5 bar in the holding tank. Dissolved oxygen is measured with an optical probe before every filtration cycle; batches exceeding 0.5 mg/L are re-sparged rather than processed. The filling line is configured with peristaltic or rotary piston pumps operating at 10–40 mL/min for 1 mL and 10 mL formats, depending on fill volume and nozzle diameter. In-process assay samples are drawn from the beginning, middle, and end of the fill run; content uniformity at these three points is required to remain within 95.0–105.0% of label claim before batch release.

Why Does Low-pH Stabilisation Limit Adrenaline Addition to Veterinary Local Anaesthetic Cartridges?

In veterinary regional anaesthesia, addition of adrenaline to lidocaine solutions for nerve blocks and dental procedures in dogs, cats, and equines requires a pH between 3.5 and 5.0 because plain local anaesthetic salt solutions are usually adjusted to 5.0–7.0 and the catecholamine demands acidic conditions. The vasoconstrictor is present at 5–20 µg/mL, expressed as 1:200,000 or 1:100,000 relative to local anaesthetic salt. Sodium metabisulfite is used at 0.05–0.1% w/v, and the cartridge headspace is overlaid with nitrogen before sealing. The pH must not exceed 5.0 during final adjustment because adrenochrome generation produces a pink-to-brown colour that is detectable spectrophotometrically before the assay limit is reached. The terminal product is filled into Type I glass cartridges with halogenated butyl rubber plungers and aluminium seals. Filling is performed aseptically where terminal steam sterilisation would reduce local anaesthetic potency or accelerate sulfite oxidation; process validation studies for terminal sterilisation in this specific adrenaline concentration range are limited. The cartridge line uses a vacuum-stoppered filling head with a residual oxygen target not exceeding 0.5% in the headspace. Filter compatibility is confirmed with dynamic contact studies because adrenaline can partition onto membrane polymers at low pH; polyethersulfone and polyvinylidene fluoride are preferred over nylon membranes, which may bind catecholamines through hydrogen bonding. Each batch is tested for pH, adrenaline assay, related substances, sterility, and particulate matter according to Ph. Eur. 3.2.1 for glass containers and Ph. Eur. 2.2.29 for chromatographic purity. The cooling of the compounding vessel to 2–8 °C during addition of adrenaline reduces oxidation kinetics and permits a processing hold time of up to 12 h before filling.

When a veterinary sublingual tablet is required, the oral solid-dose route is constrained less by drug-excipient incompatibility than by presystemic elimination, because catechol-O-methyltransferase and monoamine oxidase in the intestinal mucosa and liver reduce the systemic fraction reaching the circulation. Tablet development for veterinary use is therefore limited to sublingual or buccal administration, where the API is absorbed across the oral mucosa; no harmonised veterinary monograph currently defines a dissolution test for systemic adrenaline tablets. Direct compression with a 0.2–1.0 mg unit dose requires geometric pre-blending with a non-reducing carrier such as microcrystalline cellulose because lactose monohydrate may promote Maillard-type discolouration with secondary amines. Anhydrous dibasic calcium phosphate is used as a densification aid at 10–30% w/w to improve ejection force on a rotary press, and sodium metabisulfite is dispersed in the powder blend at 0.1% w/w before lubrication with 0.5% w/w magnesium stearate. The final blend is tested for bulk density near 0.45–0.65 g/mL, tapped density above 0.65 g/mL, and Carr index below 25% to anticipate flow problems during compression. Tablets are compressed on an instrumented rotary press at 8–12 mm diameter with B-tooling, at press speeds of 20–40 rpm, and hardness is maintained at 40–80 N for sublingual disintegration. Content uniformity is tested according to USP <905> or Ph. Eur. 2.9.40, and disintegration is assessed according to Ph. Eur. 2.9.1 or USP <701> with a disintegration time below 2 min for sublingual use. Production-scale failure modes include punch filming under low humidity and capping when magnesium stearate is over-lubricated; the latter is controlled by limiting final blend lubrication time to 3–5 min at 15–20 rpm. Published data for adrenaline-lactose Maillard kinetics in veterinary sublingual tablets is limited; industry practice therefore avoids reducing sugars in the primary powder blend without awaiting confirmatory stability data.

Low-Dose Capsule Filling and Triboelectric Segregation Control

On high-speed encapsulation lines, hard gelatin and hypromellose capsule shells are filled with adrenaline blends at total fill weights below 200 mg per unit; the API load is commonly 0.5–2.0% w/w because higher drug loads create cohesive aggregates and poor content uniformity on capsule fillers. The powder is pre-conditioned at 20–25 °C and 30–40% RH for 24 h before encapsulation. The surrounding production suite is held below 40% RH because the micronised catecholamine adsorbs moisture and forms agglomerates on dosator pins or tamping probes. Sodium stearyl fumarate is preferred over magnesium stearate at 0.5–1.0% w/w to reduce over-lubrication when the formulation contains 0.1% w/w sodium metabisulfite. Colloidal silicon dioxide is added at 0.2–0.5% w/w as a flow aid and electrostatic charge modifier. The capsule filler is operated with a dosator pin diameter of 6–8 mm at 30–60% maximum machine speed, and pin coating is monitored after each batch because static charge on the high-speed line causes powder to coat pins and produce weight variation. Capsule shells are band-sealed with gelatin to reduce oxygen ingress, and filled units are stored in amber glass or high-density polyethylene containers with nitrogen-purged headspace. Content uniformity is tested according to USP <905> or Ph. Eur. 2.9.40, and disintegration is tested according to Ph. Eur. 2.9.1 or USP <701>. Dissolution testing is not commonly specified for veterinary adrenaline capsules because the intended buccal or sublingual use is not reflected in any harmonised veterinary monograph; published data for this specific configuration is limited.

Granulated intermediates for veterinary adrenaline are dry-granulated rather than aqueous wet-granulated because water introduces the oxidative and pH conditions that destabilise the catechol. When wet granulation is unavoidable, an isopropanol-based granulating fluid is used at 20–40% w/w relative to dry powder; the solvent is removed in a vacuum tray dryer at a product temperature below 40 °C and chamber pressure below 10 kPa until loss on drying is not more than 0.5% w/w. Roller compaction is preferred for brittle formulations containing microcrystalline cellulose and dibasic calcium phosphate, with a roll force of 5–12 kN/cm and a roll speed of 2–8 rpm on pilot-scale equipment. The resulting granules are sieved through 0.8 mm and 1.25 mm screens; fines below 0.125 mm are recycled at less than 20% w/w to avoid segregation of the low-dose API. The granular intermediate is filled into unit-dose sachets or compressed into tablets under 30–40% RH, and residual solvent is verified by gas chromatography according to Ph. Eur. 2.4.24 or USP <467>. Granule flow is assessed by funnel flow rate near 10–20 g/s and tapped density near 0.55–0.75 g/mL; batches outside this range are rejected or re-screened. The terminal finished product for granules is a sublingual sachet or a tableting intermediate rather than a feed granule because the oral route is not pharmacologically rational for adrenaline.

When Premix Carriers Are Used Strictly as Compression Intermediates Rather than Feed Powders

Because oral ingestion is presystemically deactivated, adrenaline is not appropriate for medicated feed premixes; the API is also unstable under normal feed pelleting moisture and heat. However, a dry premix intermediate is used within oral solid-dose manufacture to improve blend uniformity before capsule filling or tablet compression. The carrier system comprises spray-dried mannitol or microcrystalline cellulose at 80–95% w/w, with adrenaline tartrate or base at 1–5% w/w, sodium metabisulfite at 0.1–0.5% w/w, and colloidal silicon dioxide at 0.2–0.5% w/w. Blending is performed in a bin blender at 15–25 rpm for 10–20 min, followed by a cone mill pass to disperse agglomerates and reduce low-dose segregation. The blend is held in low-density polyethylene-lined drums with nitrogen flushing, and is used within 48 h unless longer hold time is demonstrated by batch stability data. Drum headspace oxygen is checked with a handheld analyser and maintained below 1%; batches exceeding this limit are quarantined for related-substance assay. The premix intermediate is not released as a terminal veterinary feed premix; it is a controlled intermediate for subsequent solid-dose compression. Content uniformity is tested on triplicate samples from top, middle, and bottom ports according to USP <905> or Ph. Eur. 2.9.40, and particle size is verified by sieve analysis according to Ph. Eur. 2.9.12 or USP <786>. Published data on adrenaline premix hold-time in veterinary feed matrices is limited, and feed premix use is not recommended because oral bioavailability is minimal and degradation under feed-processing conditions is likely.

In perioperative irrigation, adrenaline is diluted in sterile saline for haemostasis during ocular, dental, and minor surgical procedures in veterinary practice. The surgical field uses adrenaline concentrations of 1:100,000 to 1:500,000 in saline; the solution is extemporaneously prepared because no antimicrobial preservative or long-term stabiliser is present in compounded irrigation fluids. The pH is maintained at 3.5–5.5 with citric acid/sodium citrate buffer, and the solution is filtered through a 0.22 µm sterile filter into a sterile basin or syringe immediately before use. Exposure to carbon steel instruments should be avoided because trace iron accelerates adrenochrome formation and gives a pink discolouration. The solution must not be mixed with alkaline drugs, including bicarbonate or aminophylline, because pH elevation above 6.0 produces rapid oxidation and loss of vasoconstrictor activity. For ophthalmic irrigation, the solution is prepared with preservative-free sterile saline and used within 2 h if held at room temperature; refrigerated storage at 2–8 °C may extend this to 8 h, but no veterinary pharmacopoeial stability monograph currently defines an extended-use window. The terminal finished product is a sterile field solution for local haemostasis, not a parenteral injection and not a feed or oral dosage form.